PSC

Operational & Corporate Update

Retrieved on: 
Thursday, February 2, 2023

Gulf Keystone, a leading independent operator and producer in the Kurdistan Region of Iraq (“KRI” or “Kurdistan”), today provides an operational and corporate update.

Key Points: 
  • Gulf Keystone, a leading independent operator and producer in the Kurdistan Region of Iraq (“KRI” or “Kurdistan”), today provides an operational and corporate update.
  • The information contained in this announcement has not been audited and may be subject to further review.
  • Deloitte LLP will undertake the audit of the Company for the financial year ending 31 December 2022.
  • An updated corporate presentation will be made available today on the Company’s website on the Presentations page.

Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases

Retrieved on: 
Monday, January 9, 2023

Ipsen (Euronext: IPN: ADR: IPSEY) and Albireo (Nasdaq: ALBO) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Albireo, a leading innovator in bile-acid modulators to treat pediatric and adult cholestatic liver diseases.

Key Points: 
  • Ipsen (Euronext: IPN: ADR: IPSEY) and Albireo (Nasdaq: ALBO) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Albireo, a leading innovator in bile-acid modulators to treat pediatric and adult cholestatic liver diseases.
  • “Our Rare Disease franchise is strengthened with Bylvay, which, in addition to being the first-approved treatment in PFIC, has two further indications being investigated in rare liver conditions that are underserved.
  • “Our talented team at Albireo have advanced the first Phase III studies in three different pediatric liver diseases while discovering two promising new clinical stage bile acid modulators.
  • Goldman Sachs is acting as exclusive financial advisor to Ipsen and Orrick Herrington & Sutcliffe LLP as legal counsel to Ipsen.

HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations

Retrieved on: 
Thursday, January 5, 2023

Proceeds of the financing will be used to advance multiple global development programs, including mid-to-late-stage clinical trials, and the commercialization and business development of the company's robust pipeline.

Key Points: 
  • Proceeds of the financing will be used to advance multiple global development programs, including mid-to-late-stage clinical trials, and the commercialization and business development of the company's robust pipeline.
  • "After completing a successful $60 million Series B+ round at the end of 2020, we are thrilled to have well-recognized investors participate in our C/C+ round.
  • "The Series C/C+ financing is a significant milestone for HighTide.
  • It will enable us to move aggressively to accelerate the clinical and commercial development of our innovative pipeline and external business collaborations."

Operational, Corporate & AGM Update

Retrieved on: 
Sunday, January 22, 2023

Gulf Keystone, a leading independent operator and producer in the Kurdistan Region of Iraq (“KRI”), today provides an operational, corporate and AGM update.

Key Points: 
  • Gulf Keystone, a leading independent operator and producer in the Kurdistan Region of Iraq (“KRI”), today provides an operational, corporate and AGM update.
  • Jaap Huijskes, GKP’s Non-Executive Chairman, has expressed his intention to retire from the Board following the 2023 AGM.
  • At the Company's Annual General Meeting ("AGM") held on 24 June 2022, all resolutions were successfully passed.
  • Substantially all the votes against resolutions 2 and 7 were from a single major shareholder, who voted against the re-election of the same Directors at the 2021 AGM.

SHARC Energy Applauds Transformative $1.2 Billion Development to Create 2,400 Affordable Homes, Medical Clinic, Retail in East New York

Retrieved on: 
Tuesday, January 3, 2023

The initial $373 million phase will create 576 affordable homes, a new 15,000-square-foot outpatient medical clinic, and 7,000 square feet of ground floor retail space.

Key Points: 
  • The initial $373 million phase will create 576 affordable homes, a new 15,000-square-foot outpatient medical clinic, and 7,000 square feet of ground floor retail space.
  • The initial phase of the development is comprised of two buildings with the current design having one featuring a SHARC WET System and the other a PIRANHA WET System.
  • SHARC Energy is working through the final submittal process with its New York State distributor HIGHMARK and the purchase order is expected imminently.
  • “We are appreciative of the opportunity to support the State of New York in this transformative affordable housing project.

Proactive news headlines including Bellevue Gold, Northern Minerals, Race Oncology and archTIS Ltd

Retrieved on: 
Thursday, December 22, 2022

Click here

Key Points: 
  • Click here
    Race Oncology Ltd (ASX:RAC) has provided US$541,760 in support funding to the University of Texas MD Anderson Cancer Centre, which is leading an imaging study for the detection of extramedullary Acute Myeloid Leukaemia (AML).
  • Click here
    archTIS Ltd welcomes its rebate payment of A$1.785 million from the Australian Taxation Office (ATO) relating to the company’s refundable tax offset claim for the fiscal year ending June 30, 2022.
  • Click here
    Valor Resources Ltd (ASX:VAL) has fielded high-grade rock chip results of up to 7.98% uranium described as "outstanding" at its Surprise Creek Project in Canada’s Beaverlodge Uranium District.
  • Click here
    Green Technology Metals Ltd (ASX:GT1) is trading higher after delivering lithium concentrate recovery exceeding 72% using heavy liquid separation at its flagship Seymour Project in Ontario, Canada.

Proactive news headlines including Blackstone Minerals, Elixir Energy, Magmatic Resources and Ioneer Ltd

Retrieved on: 
Tuesday, December 20, 2022

Click here

Key Points: 
  • Click here
    Moho Resources Ltd (ASX:MOH) has completed the first phase of reconnaissance drilling across exploration licence E74/695 at the Peak Charles Project, which it hopes to turn into a multi-commodity asset.
  • Click here
    Critical Resources Ltd (ASX:CRR) has executed a binding purchase and sale agreement with TSX-V lister Power Metals Corp to acquire its Gullwing-Tot Lakes property in Ontario, Canada.
  • Click here
    Peninsula Energy Ltd (ASX:PEN, OTCQB:PENMF) has completed its share purchase plan (SPP) to eligible shareholders and has raised a total of A$1 million.
  • Click here
    RemSense Technologies Ltd (ASX:REM) has been a awarded a virtualplant contract with a total value of $206,000.

West Virginia American Water Receives Approval of 2023 Distribution System Improvement Charge

Retrieved on: 
Friday, December 30, 2022

In an order entered today, the Public Service Commission of West Virginia (PSC) approved a joint agreement reached last month in West Virginia American Water’s request for approval of its 2023 infrastructure replacement program, referred to as a Distribution System Improvement Charge (DSIC).

Key Points: 
  • In an order entered today, the Public Service Commission of West Virginia (PSC) approved a joint agreement reached last month in West Virginia American Water’s request for approval of its 2023 infrastructure replacement program, referred to as a Distribution System Improvement Charge (DSIC).
  • The joint agreement was reached between West Virginia American Water, PSC staff, and the PSC’s Consumer Advocate Division.
  • “West Virginia’s infrastructure recently received a ‘D’ grade from the American Society of Civil Engineers.
  • The purpose of a DSIC is to address the national challenge of aging water infrastructure by directing additional investment to areas where improvements are most needed,” said Robert Burton, president of West Virginia American Water.

Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients

Retrieved on: 
Tuesday, January 3, 2023

TEL AVIV, Israel, Jan. 3, 2023 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today reported top-line results from its Phase 2a trial assessing CM-101, its first-in-class CCL24-neutralizing monoclonal antibody, in non-alcoholic steatohepatitis (NASH) patients. The trial met its primary endpoint of safety and tolerability, and CM-101 achieved reductions in secondary endpoints that include a range of liver fibrosis biomarkers and physiologic assessments measured at baseline and at week 20.

Key Points: 
  • The randomized, placebo-controlled trial enrolled 23 NASH patients with stage F1c, F2 and F3 disease who were randomized to receive either CM-101 or placebo.
  • Dr. Pfost continued, "This is the third clinical trial in patients demonstrating the activity of CM-101 as measured by fibro-inflammatory biomarkers and physiological assessments.
  • A Phase 2 liver fibrosis biomarker study in NASH patients was recently completed and a Phase 2 trial in primary sclerosing cholangitis patients is ongoing.
  • Chemomab expects to begin enrolling patients in a Phase 2 trial in systemic sclerosis early in 2023.

Chemomab Reports Independent Drug Monitoring Committee Safety Review of CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis

Retrieved on: 
Wednesday, December 21, 2022

TEL AVIV, Israel, Dec. 21, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that an independent Data Monitoring Committee (DMC) has completed a safety review of the company's ongoing Phase 2 trial of lead product CM-101 in primary sclerosing cholangitis (PSC) patients. The DMC had no safety concerns with proceeding with adding a planned 20 milligram per kilogram (mg/kg) dosing cohort to the PSC trial, as defined in a recent protocol amendment. The PSC trial currently has a single 10mg/kg dose, administered every three weeks by intravenous (IV) infusion.

Key Points: 
  • The DMC review was based on both blinded safety data from the PSC trial and from Chemomab's Phase 2a liver fibrosis biomarker trial in patients with non-alcoholic steatohepatitis (NASH).
  • Chemomab plans to report top-line results from this latter trial in the coming weeks.
  • The CM-101 Phase 2 SPRING trial is a randomized, placebo-controlled, multiple dose study enrolling PSC patients with large duct disease.
  • It is currently in Phase 2 trials for primary sclerosing cholangitis and liver fibrosis, with a Phase 2 trial in systemic sclerosis expected to begin enrolling patients in early 2023.